With all eyes on new Alzheimer's med, Eisai lays off 91 staffers on its Fycompa team

With an approval for Leqembi under its belt, Eisai is doubling down in Alzheimer’s disease. And that means cuts elsewhere.

Eisai is laying off 91 U.S. employees effective April 30, according to a Worker Adjustment and Retraining Notification Act (WARN) alert (PDF) from New Jersey. The public disclosure lists the location of the layoffs as Nutley, New Jersey, where Eisai recently relocated its U.S. headquarters.